JP2013503200A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503200A5
JP2013503200A5 JP2012527065A JP2012527065A JP2013503200A5 JP 2013503200 A5 JP2013503200 A5 JP 2013503200A5 JP 2012527065 A JP2012527065 A JP 2012527065A JP 2012527065 A JP2012527065 A JP 2012527065A JP 2013503200 A5 JP2013503200 A5 JP 2013503200A5
Authority
JP
Japan
Prior art keywords
seq
cancer
antibody
dnl
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527065A
Other languages
English (en)
Japanese (ja)
Other versions
JP6114936B2 (ja
JP2013503200A (ja
Filing date
Publication date
Priority claimed from US12/644,146 external-priority patent/US7981398B2/en
Priority claimed from US12/731,781 external-priority patent/US8003111B2/en
Priority claimed from US12/752,649 external-priority patent/US8034352B2/en
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed filed Critical
Priority claimed from PCT/US2010/047132 external-priority patent/WO2011026026A1/en
Publication of JP2013503200A publication Critical patent/JP2013503200A/ja
Publication of JP2013503200A5 publication Critical patent/JP2013503200A5/ja
Publication of JP6114936B2 publication Critical patent/JP6114936B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527065A 2009-08-31 2010-08-30 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法 Active JP6114936B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US23847309P 2009-08-31 2009-08-31
US61/238,473 2009-08-31
US26630509P 2009-12-03 2009-12-03
US61/266,305 2009-12-03
US12/644,146 2009-12-22
US12/644,146 US7981398B2 (en) 2005-04-06 2009-12-22 PEGylation by the dock and lock (DNL) technique
US31699610P 2010-03-24 2010-03-24
US61/316,996 2010-03-24
US12/731,781 US8003111B2 (en) 2005-04-06 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/731,781 2010-03-25
US12/752,649 US8034352B2 (en) 2005-04-06 2010-04-01 Tetrameric cytokines with improved biological activity
US12/752,649 2010-04-01
US12/754,140 2010-04-05
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
US32396010P 2010-04-14 2010-04-14
US61/323,960 2010-04-14
PCT/US2010/047132 WO2011026026A1 (en) 2009-08-31 2010-08-30 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity

Publications (3)

Publication Number Publication Date
JP2013503200A JP2013503200A (ja) 2013-01-31
JP2013503200A5 true JP2013503200A5 (https=) 2016-02-12
JP6114936B2 JP6114936B2 (ja) 2017-04-19

Family

ID=43628420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012527065A Active JP6114936B2 (ja) 2009-08-31 2010-08-30 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法

Country Status (7)

Country Link
EP (1) EP2473187A4 (https=)
JP (1) JP6114936B2 (https=)
CN (1) CN102596235A (https=)
BR (1) BR112012004274A2 (https=)
CA (1) CA2770351C (https=)
IN (1) IN2012DN01662A (https=)
WO (1) WO2011026026A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
GB201412659D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016037985A1 (en) 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
PL3258964T3 (pl) * 2015-02-16 2021-05-31 Xintela Ab Wykrywanie i leczenie nowotworów złośliwych w oun
US10202455B2 (en) * 2015-05-20 2019-02-12 Immunwork Inc. Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CN108061798B (zh) * 2016-11-07 2019-11-08 国药中生生物技术研究院有限公司 检测HBsAg/anti-HBs复合物体系中有效成分的量的方法和应用
CN107217068A (zh) * 2017-07-18 2017-09-29 哈尔滨紫霞生物科技有限公司 一种提高重组犬干扰素‑α融合蛋白抗病毒活性的方法
WO2019222533A1 (en) * 2018-05-18 2019-11-21 Okogen, Inc. Methods of treating ocular melanoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2003074566A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
WO2005080586A1 (en) * 2004-02-13 2005-09-01 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic rnases
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CN101374546B (zh) * 2005-12-16 2016-03-23 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
WO2008088658A2 (en) * 2007-01-17 2008-07-24 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
IN2012DN01331A (https=) * 2009-08-31 2015-06-05 Ibc Pharmaceuticals Inc

Similar Documents

Publication Publication Date Title
JP2013503200A5 (https=)
CN106938051B (zh) 靶向于组织因子的抗体-药物偶联物
JP2020500016A5 (https=)
Jemal et al. Cancer statistics, 2006
JP2020506727A5 (https=)
JP2017526632A5 (https=)
HRP20211346T1 (hr) Kombinirani pripravci za liječenje raka
CN111050797B (zh) 抗tim-3抗体及其用途
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2020524174A5 (https=)
JP2018527908A5 (https=)
JP2020501531A5 (https=)
JP2018529312A5 (https=)
JP2018502051A5 (https=)
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
JP2017506217A5 (https=)
JP2020525032A5 (https=)
JP2018516969A5 (https=)
JP2019514844A5 (https=)
SI2342234T1 (en) MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL
JP2009539380A5 (https=)
FI3377103T4 (fi) Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
RU2015123032A (ru) Иммунотерапия с применением связывающих агентов
JP2010536378A5 (https=)
JP2013166763A5 (https=)